Quarterly report pursuant to Section 13 or 15(d)

Condensed Statements of Operations and Comprehensive Loss (Unaudited)

v3.22.2
Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 6 Months Ended
Jun. 30, 2022
Jun. 30, 2021
Jun. 30, 2022
Jun. 30, 2021
Operating expenses:        
Research and development $ 17,777,000 $ 12,667,000 $ 36,023,000 $ 18,044,000
General and administrative 8,999,000 4,866,000 16,711,000 8,857,000
Total operating expenses 26,776,000 17,533,000 52,734,000 26,901,000
Loss from operations (26,776,000) (17,533,000) (52,734,000) (26,901,000)
Other income (expense), net:        
Other income, net 840,000 4,000 963,000 4,000
Change in fair value of the Series A redeemable convertible preferred stock tranche liability 0 0 0 (10,341,000)
Total other income (expense), net 840,000 4,000 963,000 (10,337,000)
Net loss (25,936,000) (17,529,000) (51,771,000) (37,238,000)
Unrealized loss on investments (724,000) 0 (1,033,000) 0
Comprehensive loss $ (26,660,000) $ (17,529,000) $ (52,804,000) $ (37,238,000)
Net loss per share attributable to common stockholders-basic $ (0.48) $ (3.45) $ (0.95) $ (8.45)
Net loss per share attributable to common stockholders-diluted $ (0.48) $ (3.45) $ (0.95) $ (8.45)
Weighted-average shares used in computing net loss per share-basic 54,572,866 5,087,008 54,284,836 4,405,357
Weighted-average shares used in computing net loss per share-diluted 54,572,866 5,087,008 54,284,836 4,405,357